Inhibition of vasoactive intestinal polypeptide (VIP) induces resistance to dextran sodium sulfate (DSS)-induced colitis in mice

Journal of Molecular Neuroscience

Volumn 52, Issue 1, 2014, Pages 37-47

  Vu, John P ^a   Million, Mulugeta ^a   Larauche, Muriel ^a   Luong, Leon ^a   Norris, Joshua ^a   Waschek, James A ^a   Pothoulakis, Charalabos ^a   Pisegna, Joseph R ^a,b   Germano, Patrizia M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Colitis; VIP; VIP antagonist: IBD

Indexed keywords

DEXTRAN SULFATE; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 23P19; INTERLEUKIN 6; MESSENGER RNA; PG 97 269; TRANSCRIPTION FACTOR T BET; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; [LYSINE 1, PROLINE 2,5 ARGININE 3,4, TYROSINE 6]VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COLON MUCOSA; CONTROLLED STUDY; GENE DELETION; GENE EXPRESSION; HISTOPATHOLOGY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; WILD TYPE;

MURINAE; MUS;

ANIMALS; COLITIS; CYTOKINES; DEXTRAN SULFATE; GENE DELETION; INTERLEUKINS; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED C57BL; NEUROTENSIN; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84895075379     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-013-0205-3     Document Type: Article

References (46)

1. Abad C, Martinez C, Juarranz MG et al (2003) Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 124:961-971
2. Abad C, Gomariz RP, Waschek JA (2006) Neuropeptide mimetics and antagonists in the treatment of inflammatory disease: focus on VIP and PACAP. Curr Top Med Chem 6:151-163
3. Abad C, Tan YV, Lopez R et al (2010) Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 107:19555-19560
4. Abad C, Tan YV, Cheung-Lau G, Nobuta H, Waschek JA (2012) VIP deficient mice exhibit resistance to lipopolysaccharide induced endotoxemia with an intrinsic defect in proinflammatory cellular responses. PLoS One 7:e36922
5. Alex P, Zachos NC, Nguyen T et al (2009) Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis 15:341-352
6. Andersen O, Fahrenkrug J, Wikkelsø C, Johansson BB (1984) VIP in cerebrospinal fluid of patients with multiple sclerosis. Peptides 5:435-437
7. Ballinger A (2008) Adverse effects of nonsteroidal anti-inflammatory drugs on the colon. Curr Gastroenterol Rep 10:485-489
8. Banks MR, Farthing MJ, Robberecht P, Burleigh DE (2005) Antisecretory actions of a novel vasoactive intestinal polypeptide (VIP) antagonist in human and rat small intestine. Br J Pharmacol 144:994-1001
9. Belai A, Boulos PB, Robson T, Burnstock G (1997) Neurochemical coding in the small intestine of patients with Crohn's disease. Gut 40:767-774
10. Boyer L, Sidpra D, Jevon G, Buchan AM, Jacobson K (2007) Differential responses of VIPergic and nitrergic neurons in paediatric patients with Crohn's disease. Auton Neurosci 134:106-114
11. Brandtzaeg P, Oktedalen O, Kierulf P, Opstad PK (1989) Elevated VIP and endotoxin plasma levels in human gram-negative septic shock. Regul Pept 24:37-44
12. Colwell CS, Michel S, Itri J et al (2003) Disrupted circadian rhythms in VIP- and PHI-deficient mice. Am J Physiol Regul Integr Comp Physiol 285:R939-R949
13. Delgado M, Martinez C, Johnson MC, Gomariz RP, Ganea D (1996) Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. J Neuroimmunol 68:27-38
14. Delgado M, Pozo D, Martinez C et al (1999a) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies. J Immunol 162:2358-2367
15. Delgado M, Martinez C, Leceta J, Gomariz RP (1999b) Vasoactive intestinal peptide in thymus: synthesis, receptors and biological actions. Neuroimmunomodulation 6:97-107
16. Delgado M, Pozo D, Ganea D (2004a) The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 56:249-290
17. Delgado M, Gonzalez-Rey E, Ganea D (2004b) VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells. FASEB J 18:1453-1455
18. Dieleman LA, Palmen MJ, Akol H et al (1998) Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 114:385-391
19. Gonzalez-Rey E, Fernandez-Martin A, Chorny A et al (2006) Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses. Am J Pathol 168:1179-1188
20. Gozes Y, Brenneman DE, Fridkin M, Asofsky R, Gozes I (1991) A VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes. Brain Res 540:319-321
21. Grimm MC, Newman R, Hassim Z et al (2003) Cutting edge: vasoactive intestinal peptide acts as a potent suppressor of inflammation in vivo by trans-deactivating chemokine receptors. J Immunol 17:4990-4994
22. Gross KJ, Pothoulakis C (2007) Role of neuropeptides in inflammatory bowel disease. Inflamm Bowel Dis 13:918-932
23. Harmar AJ, Fahrenkrug J, Gozes I et al (2012) Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol 166:4-17
24. Johnston JA, Taubb DD, Lloyd AR, Conlon K, Oppenheim JJ, Kevlin DJ (1994) Human T lymphocyte chemotaxis and adhesion induced by VIP. J Immunol 153:1762-1768
25. Juarranz Y, Gutiérrez-Cañas I, Santiago B, Carrión M, Pablos JL, Gomariz RP (2008) Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. Arthritis Rheum 58:1086-1095
26. Margolis KG, Gershon MD (2009) Neuropeptides and inflammatory bowel disease. Curr Opin Gastroenterol 25:503-511
27. Melgar S, Karlsson A, Michaëlsson E (2005) Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol 288:G1328-G1338
28. Melgar S, Karlsson L, Rehnström E et al (2008) Validation of murine dextran sulfate sodium-induced colitis using four therapeutic agents for human inflammatory bowel disease. Int Immunopharmacol 8:836-844
29. Moody TW, Jensen RT, Fridkin M, Gozes I (2002) (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist. J Mol Neurosci 18:29-35
30. Moody TW, Zia F, Draoui M et al (2003) A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth. Proc Natl Acad Sci U S A 90:4345-4349
31. Newman R, Cuan N, Hampartzoumian T, Connor SJ, Lloyd AR, Grimm MC (2005) Vasoactive intestinal peptide impairs leucocyte migration but fails to modify experimental murine colitis. Clin Exp Immunol 139:411-420
32. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R (1990) A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98:694-702
33. Ottaway CA, Lewis DL, Asa SL (1987) Vasoactive intestinal peptide-containing nerves in Peyer's patches. Brain Behav Immun 1:148-158
34. Perrier C, Rutgeerts P (2012) New drug therapies on the horizon for IBD. Dig Dis 30(Suppl 1):100-105
35. Perše M, Cerar A (2012) Dextran sodium sulphate colitis mouse model: traps and tricks. J Biomed Biotechnol 2012:718617
36. Reshef R, Varkel J, Shiller M, Loberant N (1992) Systemic effects of rectally administered corticosteroids. Isr J Med Sci 28:98-100
37. Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3:1101-1108
38. Törnwall J, Uusitalo H, Hukkanen M, Sorsa T, Konttinen YT (1994) Distribution of vasoactive intestinal peptide (VIP) and its binding sites in labial salivary glands in Sjögren's syndrome and in normal controls. Clin Exp Rheumatol 12:287-292
39. Truelove SC (1960) Systemic and local corticosteroid therapy in ulcerative colitis. Br Med J 1:464-467
40. Von der Weid PY, Rehal S, Dyrda P et al (2012) Mechanisms of VIP-induced inhibition of the lymphatic vessel pump. J Physiol 590:2677-2691
41. Wang JM, McVicar DW, Oppenheim JJ, Kelvin DJ (1993) Identification of RANTES receptors on human monocytic cells: competition for binding and desensitization by homologous chemotactic cytokines. J Exp Med 177:699-705
42. Waschek J (2013) VIP and PACAP: neuropeptide modulators of CNS inflammation, injury and repair. Br J Pharmacol 169:512-523
43. Yadav M, Huang MC, Goetzl EJ (2011) VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis. Cell Immunol 267:124-132
44. Yukawa T, Oshitani N, Yamagami H, Watanabe K, Higuchi K, Arakawa T (2007) Differential expression of vasoactive intestinal peptide receptor 1 expression in inflammatory bowel disease. Int J Mol Med 20:161-167
45. Zia H, Hida T, Jakowlew S et al (1996) Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. Cancer Res 56:3486-3489
46. Zia H, Leyton J, Casibang M et al (2000) (N-stearyl, norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines. Life Sci 66:379-387